RecruitingPhase 4NCT05858632
Immune Spatial Features of Guselkumab Cutaneous Response
Sponsor
University of California, San Francisco
Enrollment
10 participants
Start Date
Jul 1, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
This study examines the effect of IL-23 blockade with Guselkumab on the immune cells of scalp psoriasis lesions.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called Guselkumab for people with psoriasis of scalp. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGGuselkumab
Guselkumab treatment for \~ 9 months
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05858632